Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.

Article  PubMed  PubMed Central  Google Scholar 

Kumar S, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:1317–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sidana S, Narkhede M, Elson P, Hastings D, Faiman B, Valent J, et al. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE. 2017;12:e0172996.

Article  PubMed  PubMed Central  Google Scholar 

Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, et al. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leuk Lymphoma. 2020;61:680–90.

Article  CAS  PubMed  Google Scholar 

Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, et al. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. Am J Hematol. 2021;96:330–7.

Article  CAS  PubMed  Google Scholar 

Hoff FW, Banerjee R, Khan AM, McCaughan GJ, Wang X, Roose J, et al. Retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma. Blood. 2023;141:544.

Google Scholar 

Taylor C. The use of clinical practice guidelines in determining standard of care. J Leg Med. 2014;35:273–90.

Article  PubMed  Google Scholar 

Moffett P, Moore G. The standard of care: legal history and definitions: the bad and good news. West J Emerg Med. 2011;12:109–12.

PubMed  PubMed Central  Google Scholar 

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100:964–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Bank. World Bank Country and Lending Groups. World Bank;2023. [Cited 2023 Oct 24]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519.

Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13:46.

Article  PubMed  PubMed Central  Google Scholar 

McCaughan GJ, Gandolfi S, Moore JJ, Richardson PG. Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. Br J Haematol. 2022;199:190–204.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–28.

Article  CAS  PubMed  Google Scholar 

Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396:1563–73.

Article  CAS  PubMed  Google Scholar 

Food and Drug Administration. Docket FDA-2006-D-0031. Informed Consent: Draft Guidance for IRBs, Clinical Investigators, and Sponsors. Food and Drug Administration;2023 [Cited 2023 Oct 24]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent#_ftn14.